ARCHIVES

Phase III Study Evaluating Halaven Fails To Meet Primary Endpoints

This article is from The Cancer Letter archive.

Vol. 35 No. 7 | July 27, 2012

Download PDF Visit The Full Archive

Related Articles

Dose Dense Chemo Study Published Early; Method Improves Breast Cancer Survival

February 28, 2003

Group Chairs Respond to Center Directors’ White Paper

April 1, 2011

STI-571 Effects Are Lasting Against GI Stromal Tumors

July 26, 2002

NCCS Networker Volume 1 Issue 3, Fall 1987

September 13, 1987

New CREG Announcements Made By NCI

October 3, 1975

Drugs and Targets: FDA extends Lymphoseek label to include mapping in solid tumors

October 31, 2014